BNP/CALL/ROCHE GS/280/0.1/20.12.24 Stock

Warrant

DE000PN7C7U9

Delayed Deutsche Boerse AG 03:20:59 2024-07-17 am EDT
1.23 EUR +92.19% Intraday chart for BNP/CALL/ROCHE GS/280/0.1/20.12.24
Current month+39.13%
1 month+28.00%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes
Date Price Change
24-07-17 1.23 +92.19%
24-07-16 0.64 -4.48%
24-07-15 0.67 +17.54%
24-07-12 0.57 +18.75%
24-07-11 0.48 +14.29%

Delayed Quote Deutsche Boerse AG

Last update July 17, 2024 at 03:20 am EDT

More quotes

Static data

Product typeWarrants
Buy / SellCALL
Underlying ROCHE HOLDING AG
IssuerLogo Issuer BNP Paribas BNP Paribas
WKN PN7C7U
ISINDE000PN7C7U9
Date issued 2023-08-16
Strike 280 CHF
Maturity 2024-12-20 (157 Days)
Parity 10 : 1
Emission price 1.42
Emission volume N/A
Settlement règlement en espèces
Currency EUR

Technical Indicators

Highest since issue 1.57
Lowest since issue 0.12
Delta0.31x
Omega 12.57
Premium10.65x
Gearing39.93x
Moneyness 0.9246
Difference Strike 8.5 CHF
Difference Strike %+3.04%
Spread 0.01
Spread %1.49%
Intrinsic value 0.000000

Company Profile

Roche Holding AG (Roche) is a research-based healthcare company. The Company's operating businesses are organized into two divisions: Pharmaceuticals and Diagnostics. The Pharmaceuticals Division consists of two business segments: Roche Pharmaceuticals and Chugai. The Diagnostics Division consists of four business areas: Diabetes Care, Molecular Diagnostics, Professional Diagnostics and Tissue Diagnostics. The Company develops medicines for various disease areas, including oncology, immunology, infectious diseases, ophthalmology and neuroscience. Its pharmaceutical products include Anaprox, Avastin, Bactrim, Bondronat, CellCept, Cotellic, Dilatrend, Dormicum, Invirase, Kadcyla, Kytril (Kevatril), Lariam, MabThera, Madopar, Neupogen, Pegasys, Perjeta, Pulmozyme, Rocaltrol, Rocephin and Roferon-A. The Company offers products for researchers, including cell analysis, gene expression, genome sequencing and nucleic acid purification.
Sector
-
More about the company

Ratings for Roche Holding AG

Trading Rating
Investor Rating
ESG Refinitiv
A+
More Ratings

Consensus: Roche Holding AG

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
20
Last Close Price
258.9 CHF
Average target price
274 CHF
Spread / Average Target
+5.83%
Consensus